Actinium Presents New Pivotal Phase 3 SIERRA Trial Data Showing Rapid Peripheral Blast Reduction and Anti-Leukemic Effect with Single Agent Iomab-B in Older Patients with Active\, Relapsed or Refractory Acute Myeloid Leukemia at 2019 ASCO